ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

FDA, CMS Take Second Look at Drugs Given “Accelerated” Approval for Cancer

March 21, 2003

Moses To Lead AACI.

October 19, 2001

HHS News: Skin Cancer Awareness Initiative Begun

May 29, 1998

Army Breast Cancer Program Seeks Grants Applicants

May 17, 1996

NSABP Accrual Slow, But Auditing Called “Impressive”

January 20, 1995

FDA Rejects Genentech Bid For Accelerated Approval For T-DM1. NCI Breaks Ground For Satellite Campus At Shady Grove

September 3, 2010